Abstract
The previous chapters have demonstrated that physical chemistry, engineering, and consequently the regulatory considerations are required to develop pharmaceutical products; when scrutinized closely it involves complex and confounding variables that require a high level of control.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Altshuler D, Pollara VJ, Cowles CR, Van Etten WJ, Baldwin J et al (2000) An SNP map of the human genome generated by reduced representation shotgun sequencing. Nature 407:513–516
Anderson RM, May RM (1979) Population biology of infectious disease: Part I. Nature 280:361–367
Cole ST, Brosch R, Parkhill R, Garnier T, Churcher C et al (1998) Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393:537–544
Dokoumetzidis A, Macheras P (2006) A comment on “Adverse drug reactions and avalanches: life at the edge of chaos”. J Clin Pharmacol 46(9):1057–1058, author reply 1059–1060
Evans WE, Relling MV (2004) Moving toward individualized medicine with pharmacogenomics. Nature 429:464–468
Frattarelli DA (2005) Adverse drug reactions and avalanches: life at the edge of chaos. J Clin Pharmacol 45(8):866–871
Gatenby RA, Vincent TL (2003) Application of quantitative models from population biology and evolutionary game theory to tumor therapeutic strategies. Mol Cancer Ther 2:919–927
Glattre E, Nygard JF (2004) Fractal meta-analysis and ‘causality’ embedded in complexity: advanced understanding of disease etiology. Nonlinear Dynamics Psychol Life Sci 8(3):315–344
Hirano T (2007) Cellular pharmacodynamics of immunosuppressive drugs for individualized medicine. Int Immunopharmacol 7:3–22
Kennedy T (1998) Pharmaceutical project management. Dekker, New York
Levy S, Sutton G, Ng PC, Feuk L, Halpern AL et al (2007) The diploid genome sequence of an individual human. PLoS Biol 5(10):e254. doi:10.1371/journal.pbio 0050254
May RM, Anderson RM (1979) Population biology of infectious disease: Part II. Nature 280:455–461
O’Donovan C, Apweiler R, Bairoch A (2001) The human proteomics initiative (HPI). Trends Biotechnol 19:178–181
Pearson H (2007) Meet the human metabolome. Nature 446:8. doi:101038/446008a
Turnbull C, Ahmed S, Morrison J, Pernet D, Renwick A et al (2010) Genome-wide association study identifies five new breast cancer susceptible loci. Nat Genet. doi:10.1038/ng.586
Venter JC, Adams MD, Myers EW, Li PW, Muraj RJ et al (2001) The sequence of the human genome. Science 291:1304–1351
Vesper JL (2006) Risk assessment and risk management in the pharmaceutical industry: clear and simple. Parenteral Drug Association, Washington
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2011 American Association of Pharmaceutical Scientists
About this chapter
Cite this chapter
Hickey, A.J., Smyth, H.D.C. (2011). Impact of Complexity on Population Biology. In: Pharmaco-Complexity. Outlines in Pharmaceutical Sciences, vol 1. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-7856-1_6
Download citation
DOI: https://doi.org/10.1007/978-1-4419-7856-1_6
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4419-7855-4
Online ISBN: 978-1-4419-7856-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)
